Brentuximab vedotin (Genetical Recombination)
Sponsors
Takeda
Conditions
Pediatric Hodgkin LymphomaPeripheral T Cell LymphomaUntreated CD30-Positive Hodgkin's Lymphoma
Unknown Phase
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's Lymphoma
CompletedNCT03729609
Start: 2018-11-01End: 2023-09-27Updated: 2024-08-21
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma
CompletedNCT04213209
Start: 2020-02-14End: 2023-12-13Updated: 2024-09-27